Browsing by Subject "Pap smear"
Results Per Page
Sort Options
Item Open Access Cervical Cancer Detection and Prevention in Haiti: A Comparison of Pap Smear and Liquid-Based Cytology Detection Methods(2015) Wolpert, GenevieveHuman Papillomavirus-induced cervical cancer represents one of the most significant causes of female morbidity and mortality from cancer worldwide. Detecting HPV-related cervical disease during the premalignant treatable stage of development is critical to reduce the burden of this disease. Cervical cytology has been the primary screening tool for cervical dysplasia in the United States for decades. However in Haiti, early attempts to identify cervical dysplasia were thwarted by a high incidence of obscuring inflammation on conventional Pap smears. This study seeks to determine if liquid-based cytology screening can increase the detection of cervical dysplasia over conventional Pap smears when obscuring inflammation is present. The study population was recruited in Haiti and women underwent both types of cervical dysplasia testing; those for whom it was indicated underwent follow-up cervical biopsy. The cervical dysplasia tests were compared to each other using kappa agreement statistics with cervical biopsy as the gold standard for diagnosis. Both tests showed comparable sensitivity for dysplasia with and without inflammation-containing samples. The Pap test showed superior specificity by greater agreement with the gold standard biopsy, though the sample size was small. Interpretation of these results and application to a low-resource setting for implementation of a standardized screening regimen would require a larger sample size and cost/benefit analysis.
Item Open Access Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers.(MDM policy & practice, 2020-07) Holt, Hunter K; Kulasingam, Shalini; Sanstead, Erinn C; Alarid-Escudero, Fernando; Smith-McCune, Karen; Gregorich, Steven E; Silverberg, Michael J; Huchko, Megan J; Kuppermann, Miriam; Sawaya, George FPurpose. In 2018, the US Preventive Services Task Force (USPSTF) endorsed three strategies for cervical cancer screening in women ages 30 to 65: cytology every 3 years, testing for high-risk types of human papillomavirus (hrHPV) every 5 years, and cytology plus hrHPV testing (co-testing) every 5 years. It further recommended that women discuss with health care providers which testing strategy is best for them. To inform such discussions, we used decision analysis to estimate outcomes of screening strategies recommended for women at age 30. Methods. We constructed a Markov decision model using estimates of the natural history of HPV and cervical neoplasia. We evaluated the three USPSTF-endorsed strategies, hrHPV testing every 3 years and no screening. Outcomes included colposcopies with biopsy, false-positive testing (a colposcopy in which no cervical intraepithelial neoplasia grade 2 or worse was found), treatments, cancers, and cancer mortality expressed per 10,000 women over a shorter-than-lifetime horizon (15-year). Results. All strategies resulted in substantially lower cancer and cancer death rates compared with no screening. Strategies with the lowest likelihood of cancer and cancer death generally had higher likelihood of colposcopy and false-positive testing. Conclusions. The screening strategies we evaluated involved tradeoffs in terms of benefits and harms. Because individual women may place different weights on these projected outcomes, the optimal choice for each woman may best be discerned through shared decision making.